Vivus Stock Up On Qsymia Heart Disease Study
Shares of Vivus (VVUS) were up 1.5% in early trading Friday, after being up nearly 6%, after a study indicated its obesity drug Qsymia reduced certain risk factors for heart disease. The study, whose abstract is available online, indicated that patients who took Qsymia for over a year showed improved blood pressure, cholesterol and triglyceride levels, in addition to significant weight loss. All of these are risk factors for cardiovascular
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here